“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Respiri
Respiri is an Australia-based medical device and SaaS company focused on respiratory health management through its integrated wheezo platform. Its technology records data such as wheeze rates, breath recordings and other environmental factors and medication usage. Wheezo was launched in the US in December 2021.
Respiri — 1 video in collection
Respiri is an ASX-listed company developing software as a service (SaaS) diagnostic solutions to support respiratory health management. The company’s technology detects wheeze, a typical symptom of asthma, chronic obstructive pulmonary disease and respiratory disease, to provide an objective measure of airway limitation. In this video, CEO Marjan Mikel provides an overview of the company’s strategy and approach.
Get access to the very latest content matched to your personal investment style.
